Authors : Aneth Barongo; Gideon Kwesigabo

Volume/Issue : Volume 10 - 2025, Issue 4 - April

Google Scholar : https://tinyurl.com/57m2bbxm

DOI : https://doi.org/10.38124/ijisrt/25apr1931

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Background: Globally, HIV/ AIDS continues to be a public health problem and as of June 2023 Iringa has a total of 81,852 clients receiving Care and treatment from DHIS2 source. Antiretroviral therapy (ART) is the backbone of management of HIV and clients need to have high adherence (≥ 95%) for ART treatment outcome to be positive. Most previous studies have identified that Lost to follow up (LTFU) from ART treatment programs is the main challenge faced by most ART treatment programs in resource constrained countries. Tanzania is reported to have high rate of LTFU among PLHIV on ART, and factors associated with LTFU in areas with high prevalence of HIV/AIDs like Iringa region are not well known and documented  Objectives: This study intends to estimate the incidence rate of LTFU among PLHIV on ART and to identify factors associated with LTFU in Iringa region, Tanzania.  Method and Materials: The Study design was a retrospective cohort design among PLHIV initiated in treatment from 2017 to 2020 in Iringa region. The regional HIV treatment dataset was retrieved from CTC2 electron database in excel format, cleaned, coded and imported into IBM SPSS STATISTICS version 26 for analysis. Numerical variables were summarized using median (IQR) while categorical variables were analyzed and reported as proportions. Incidence rates were calculated and used as measure of magnitude of the problem, while survival analysis and log-rank tests were used to compare rate of LTFU among adult living with HIV on ART with different level of initial exposures. Any variable associated with LTFU at significant level of P < 0.2 in univariate analysis was subjected to multivariate Cox proportion regression analysis in order to control potential confounders. Any variable which showed association with LTFU at significant level of p value < 0.05 in multivariate Cox regression analysis was regarded as independently associated with LTFU  Results: A total of 36,043 participants were included in the analysis, the overall incidence rate of lost to follow up among adult PLHIV initiated ARV is 2.80, 95% CI (2.68 – 2.93) per 100-person years. This incidence rate was observed to vary based on duration of follow up (time), age, sex and residence. LTFU increased with increasing time of follow, it was 0.34, 95% CI (0.26 – 0.44) per 100 person-years at initial 6 months of follow up, then increased to 1.59, 95% CI (1.40 – 1.81) per 100 person-years at 6 – 12 months of follow up, which increased further to 2.56, 95% CI (2.35 – 2.78) per 100 person-years at 12 – 24 months of follow up, and the highest incidence was 4.45, 95% CI (4.08 – 4.85) per 100 person-years, which was observed at the 24 – 36 months of follow up. In terms of factors associated with LTFU, young age (aged 18 – 24 years) at the time of ARV initiation (adjusted HR = 3.95, 95% CI 2.95– 5.28, P < 0.001, residents of Mufindi DC (adjusted HR = 1.39, 95% CI 1.16 – 1.66, P < 0.001), Mafinga TC (adjusted HR = 4.04, 95% CI 3.3 – 4.90, P < 0.001), and Kilolo DC (adjusted HR = 2.11, 95% CI 1.77 – 2.53, P < 0.001), as well as PLHIV initiated NNRTI antiretroviral regimen (adjusted HR = 2.93, 95% CI 2.64 – 3.26, P < 0.001) and PLHIV at WHO clinical stage I (adjusted HR = 3.77, 95% CI 2.80 – 5.09, P < 0.001), stage II (adjusted HR = 2.59, 95% CI 1.89 – 3.53, P < 0.001) and stage III (adjusted HR = 1.62, 95% CI 1.21 – 2.17, P = 0.001) at the time of ARV initiation, were significantly associated with increased Hazard Ratio (HR) of being LTFU. Conclusion and Recommendation: LTFU remains a challenge in care and treatment of PLHIV in the studied area. Younger age, male sex, PLHIV initiated NNRTI-regimen and PLHIV residing in Mufindi DC, Mafinga TC and Kilolo DC were factors associated with increased risk of LTFU. Moreover, Lost to Follow Up is shown to decrease with increasing WHO stage at recruitment. Interventions targeting these factors are important to address the problem

Keywords : Lost to Follow Up, People Living with HIV, Anti Retro Viral Treatment.

References :

1. UNAIDS. Global HIV & AIDS statistics — 2020 fact sheet 2020 [Available from: https://www.unaids.org /en/resources/fact-sheet.
2. Avert. HIV and AIDS in East and Southern Africa regional overview 2020, August 25 [        Available from: https://www. avert.org/professionals/hiv-around-world/sub-saharan-africa/overview.
3. UNAIDS. United Republic of Tanzania 2020 [Available from: https://www.unaids.org/en/regions countries/countries/unitedr epublicoftanzania.
4. May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS (London, England). 2014;28(8):1193.
5. Loutfy MR, Wu W, Letchumanan M, Bondy L, Antoniou T, Margolese S, et al. Systematic review of HIV transmission between heterosexual serodi scordant couples where the HIV-positive partner is fully suppressed on antiretroviral therapy. PloS one. 2013;8(2):e55747.
6. Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Van Lunzen J, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. Jama. 2016;316 (2):171-81.
7. World Health Organization. Antiretroviral therapy (ART) coverage among all age groups 2020 [Available from: https://www.who.int/gho/hiv/epidemic_respo nse/ART/en/.
8. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub‐Saharan Africa, 2007–2009: systematic review. Tropical medicine & international health. 2010;15:1-15.
9. Alvarez-Uria G, Naik PK, Pakam R, Midde M. Factors associated with attrition, mortality, and loss to follow up after antiretroviral therapy initiation: data from an HIV cohort study in India. Glob Health Action. 2013;6:21682.
10. Somi G, Keogh S, Todd J, Kilama B, Wringe A, Van Den Hombergh J, et al. Low mortality risk but high loss to follow‐up among patients in the Tanzanian national HIV care and treatment programme. Tropical Medicine & International Health. 2012;17(4):497-506.
11. Avert. HIV and AIDS in East and Southern Africa regional overview 2020 [Available from: https://www .ave rt.org/professionals/hiv-around-world/sub-sahar an-africa/overview.
12. UNAIDS. UNAIDS DATA 2017. 2017.
13. UNAIDS. Ending AIDS progress towards the 90-90-90 targets. 2017.
14. Marsh K, Eaton JW, Mahy M, Sabin K, Autenrieth CS, Wanyeki I, et al. Global, regional and country-level 90–90–90 estimates for 2018: assessing progress towards the 2020 target. AIDS. 2019;33:S213-S26.
15. Joint United Nations Programme on HIV/AIDS. 90-90-90: an ambitious treatment target to help end the AIDS epidemic. October 2014. 2018.
16. Hamlyn E, Ewings FM, Porter K, Cooper DA, Tambussi G, Schechter M, et al. Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PLoS One. 2012;7(8):e43754.
17. Chammartin F, Zürcher K, Keiser O, Weigel R, Chu K, Kiragga AN, et al. Outcomes of patients lost to follow-up in African antiretroviral therapy programs: individual patient data meta-analysis. Clinical infectious diseases. 2018;67(11):1643-52.
18. Geng EH, Bangsberg DR, Musinguzi N, Emenyonu N, Bwana MB, Yiannoutsos CT, et al. Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. Journal of acquired immune deficiency syndromes (1999). 2010;53(3):405.
19. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. The Lancet. 2010;375(9731):2092-8.
20. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. New England journal of medicine. 2011;365(6):493-505.
21. Kiwanuka J, Mukulu Waila J, Muhindo Kahungu M, Kitonsa J, Kiwanuka N. Determinants of loss to follow-up among HIV positive patients receiving antiretroviral therapy in a test and treat setting: A retrospective cohort study in Masaka, Uganda. PLoS One. 2020;15(4):e0217606.
22. Berheto TM, Haile DB, Mohammed S. Predictors of Loss to follow-up in Patients Living with HIV/AIDS after Initiation of Antiretroviral Therapy. N Am J Med Sci. 2014;6(9):453-9.
23. Kamacooko O, Mayanja Y, Bagiire D, Namale G, Hansen CH, Seeley J. Predictors of lost to follow-up in a "test and treat" programme among adult women with high-risk sexual behavior in Kampala, Uganda. BMC Public Health. 2020;20(1):353.
24. Kalinjuma AV, Glass TR, Weisser M, Myeya SJ, Kasuga B, Kisung'a Y, et al. Prospective assessment of loss to follow-up: incidence and associated factors in a cohort of HIV-positive adults in rural Tanzania. J Int AIDS Soc. 2020;23(3):e25460.
25. Kiwanuka G, Kiwanuka N, Muneza F, Nabirye J, Oporia F, Odikro MA, et al. Retention of HIV infected pregnant and breastfeeding women on option B+ in Gomba District, Uganda: a retrospective cohort study. BMC Infect Dis. 2018;18(1):533.
26. Krishnan S, Wu K, Smurzynski M, Bosch R, Benson C, Collier A, et al. Incidence rate of and factors associated with loss to follow-up in a longitudinal cohort of antiretroviral-treated HIV-infected persons: an AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) analysis. HIV clinical trials. 2011;12(4):190-200.
27. Arnesen R, Moll AP, Shenoi SV. Predictors of loss to follow-up among patients on ART at a rural hospital in KwaZulu-Natal, South Africa. PLoS One. 2017;12(5):e0177168.
28. Vanobberghen F, Weisser M, Kasuga B, Katende A, Battegay M, Tanner M, et al. Mortality in a Cohort of People Living with HIV in Rural Tanzania, Accounting for Unseen Mortality Among Those Lost to Follow-up. American Journal of Epidemiology. 2020.
29. Tweve EN, Kayabu D, Nassari NO, Todd J. Improvement in mortality and retention among adult HIV-infected patients in the first 12 months of antiretroviral therapy in Dodoma urban district, Tanzania. Trop Med Int Health. 2015;20(6):791-6.
30. Mancinelli S, Nielsen‐Saines K, Germano P, Guidotti G, Buonomo E, Scarcella P, et al. Who will be lost? Identifying patients at risk of loss to follow‐up in Malawi. The DREAM Program Experience. HIV medicine. 2017;18(8):573-9.
31. Ojwang’ V, Penner J, Blat C, Agot K, Bukusi E, Cohen C. Loss to follow-up among youth accessing outpatient HIV care and treatment services in Kisumu, Kenya. AIDS care. 2016;28(4):500-7.
32. Hassan AS, Fielding KL, Thuo NM, Nabwera HM, Sanders EJ, Berkley JA. Early loss to follow‐up of recently diagnosed HIV‐infected adults from routine pre‐ART care in a rural district hospital in Kenya: a cohort study. Tropical medicine & international health. 2012;17(1):82-93.
33. Rispel LC, Cloete A, Metcalf CA. ‘We keep her status to ourselves’: Experiences of stigma and discrimination among HIV-discordant couples in South Africa, Tanzania and Ukraine. SAHARA-J: Journal of Social Aspects of HIV/AIDS. 2015;12(1):10-7.
34. Tomori C, Kennedy CE, Brahmbhatt H, Wagman JA, Mbwambo JK, Likindikoki S, et al. Barriers and facilitators of retention in HIV care and treatment services in Iringa, Tanzania: the importance of socioeconomic and sociocultural factors. AIDS Care. 2014;26(7):907-13.
35. Opio D, Semitala FC, Kakeeto A, Sendaula E, Okimat P, Nakafeero B, et al. Loss to follow-up and associated factors among adult people living with HIV at public health facilities in Wakiso district, Uganda: a retrospective cohort study. BMC health services research. 2019;19(1):628.
36. Ostermann J, Whetten K, Reddy E, Pence B, Weinhold A, Itemba D, et al. Treatment retention and care transitions during and after the scale-up of HIV care and treatment in Northern Tanzania. AIDS Care. 2014;26(11):1352-8.
37. Koole O, Tsui S, Wabwire-Mangen F, Kwesigabo G, Menten J, Mulenga M, et al. Retention and risk factors for attrition among adults in antiretroviral treatment programmes in Tanzania, Uganda and Zambia. Trop Med Int Health. 2014;19(12):1397-410.
38. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PloS one. 2009;4(6):e5790.
39. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clinical Infectious Diseases. 2003;37(8):1112-8.
40. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. The Lancet. 2009;373(9657):48-57.
41. Estill J, Tweya H, Egger M, Wandeler G, Feldacker C, Johnson LF, et al. Tracing of patients lost to follow-up and HIV transmission: mathematical modeling study based on 2 large ART programs in Malawi. Journal of acquired immune deficiency syndromes (1999). 2014;65(5):e179-e86.
42. Armstrong WS, Del Rio C. Patient Tracking as a Tool to Improve Retention in Care: Is the Juice Worth the Squeeze? : Oxford University Press US; 2017.
43. City Population. Tanzania: Regions and Cities 2020 July, 25 [Available from: https://www.cityp opulation .de/en/tanzania/cities/.
44. Tanzania Commission for AIDS (TACAIDS) & Zanzibar AIDS Commission (ZAC). Tanzania HIV Impact Survey (THIS) 2016-2017. Dar es Salaam, Tanzania; 2018 December.
45. Schöni-Affolter F, Keiser O, Mwango A, Stringer J, Ledergerber B, Mulenga L, et al. Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: the effect of the competing risk of death in Zambia and Switzerland. PloS one. 2011;6 (12):e27919.
46. Sahai H, Khurshid A. Formulae and tables for the determination of sample sizes and power in clinical trials for testing differences in proportions for the two‐sample design: a review. Statistics in medicine. 1996;15(1):1-21.
47. Schlesselman JJ. Case-control studies: design, conduct, analysis: Oxford university press; 1982.
48. Agolory SG, Auld AF, Odafe S, Shiraishi RW, Dokubo EK, Swaminathan M, et al. High rates of loss to follow-up during the first year of pre-antiretroviral therapy for HIV patients at sites providing pre-ART care in Nigeria, 2004-2012. PLoS One. 2017;12 (9):e0183823.
49. Chauke P, Huma M, Madiba S. Lost to follow up rate in the first year of ART in adults initiated in a universal test and treat programme: a retrospective cohort study in Ekurhuleni District, South Africa. The Pan African Medical Journal. 2020;37.
50. Nshimirimana C, Ndayizeye A, Smekens T, Vuylsteke B. Loss to follow‐up of patients in HIV care in Burundi: A retrospective cohort study. Tropical Medicine & International Health. 2022.
51. Tesha E-D, Kishimba R, Njau P, Revocutus B, Mmbaga E. Predictors of loss to follow up from antiretroviral therapy among adolescents with HIV/AIDS in Tanzania. PLOS ONE. 2022;17 (7):e0268825.
52. Kebede HK, Mwanri L, Ward P, Gesesew HA. Predictors of lost to follow up from antiretroviral therapy among adults in sub-Saharan Africa: a systematic review and meta-analysis. Infectious diseases of poverty. 2021;10(1):1-18.
53. Jiamsakul A, Kiertiburanakul S, Ng OT, Chaiwarith R, Wong W, Ditangco R, et al. Long-term loss to follow-up in the TREAT Asia HIV Observational Database (TAHOD). HIV Med. 2019;20(7):439-49.
54. Claborn KR, Meier E, Miller MB, Leffingwell TR. A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy. Psychol Health Med. 2015;20(3):255-65.
55. Stevens PE, Hildebrandt E. Pill Taking From the Perspective of HIV-Infected Women Who Are Vulnerable to Antiretroviral Treatment Failure. Qualitative Health Research. 2009;19(5):593-604.
56. Hong SY, Winston A, Mutenda N, Hamunime N, Roy T, Wanke C, et al. Predictors of loss to follow-up from HIV antiretroviral therapy in Namibia. Plos one. 2022;17(4):e0266438.
57. Teshale AB, Tsegaye AT, Wolde HF. Incidence and predictors of loss to follow up among adult HIV patients on antiretroviral therapy in University of Gondar Comprehensive Specialized Hospital: A competing risk regression modeling. PLoS One. 2020;15(1):e0227473.
58. Dayyab FM, Mukhtar F, Iliyasu G, Habib AG. Determinants of loss to follow-up among people living with HIV on antiretroviral therapy in Nigeria. African Journal of AIDS Research. 2021;20(1):93-9.
59. Serrano-Villar S, Martínez-Sanz J, Ron R, Talavera-Rodríguez A, Fernández-Felix BM, Herrera S, et al. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study. The Lancet HIV. 2020;7(8):e565-e73.
60. Desta AA, Woldearegay TW, Futwi N, Gebrehiwot GT, Gebru GG, Berhe AA, et al. HIV virological non-suppression and factors associated with non-suppression among adolescents and adults on antiretroviral therapy in northern Ethiopia: a retrospective study. BMC Infectious Diseases. 2020;20(1):4.
61. ASHM. Antiretroviral Guidelines; Adverse Effects of Antiretroviral Agents 2018 [updated October 25, 2018. Available from: https://arv.ashm.org.au/adverse-effects-of-antiretroviral-agents/.
62. Birhanu MY, Leshargie CT, Alebel A, Wagnew F, Siferih M, Gebre T, et al. Incidence and predictors of loss to follow-up among HIV-positive adults in northwest Ethiopia: a retrospective cohort study. Tropical medicine and health. 2020;48(1):1-10.